research Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
Search
for
Sort by
Research
30-60 / 266 results 
research Current Best Evidence in Pigmentary Dermatology
Several treatments are effective for pigmentary disorders like vitiligo and melasma.
research Treatment Preferences of Adults and Adolescents with Alopecia Areata: A Discrete Choice Experiment
Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
research Effects of Natural Herbal Marker Compounds on Human Dermal Papilla Cell Growth Regulation
Four natural compounds were found to promote hair growth effectively.
research Use of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research Discovery Of A Novel And Highly Selective JAK3 Inhibitor As A Potent Hair Growth Promoter
MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
research Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
research Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction
Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
research Molecular Profiling of Frontal Fibrosing Alopecia Reveals TH1 and JAK-STAT Up-Regulation with No Suppression of Hair Keratins
Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research In-Silico Screening of ATP-Competitive Inhibitory Activities of Phytochemicals Against Janus Kinase 3 and Its In-Vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Cedrol in Ginger (Zingiber Officinale) as a Promising Hair Growth Drug: The Effects of Oral and External Administration on Hair Regeneration and Its Mechanism
Cedrol from ginger can promote hair growth when taken orally.
research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
research Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth
Blocking JAK-STAT signaling can lead to hair growth.
research Janus Kinase Inhibitors in Dermatology: A Systematic Review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism
Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
research Safety of Janus Kinase Inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research An Open-Label Pilot Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Effect of Tofacitinib on the Expression of Noggin/BMP-4 and Hair Growth Stimulation in Mice
Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.